|
|
Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
原文:
Presently 45 candidate COVID-19 vaccines are in clinical trials in humans and ten of these vaccines are in phase 3 trials, with expectations that some results might be announced before the end of 2020. If the results of the phase 3 trials are satisfactory, wide-scale deployment of COVID-19 vaccines is not expected until mid to late 2021.Developing the structure of a within-country immunisation programme will be crucial, including defining priorities for receiving vaccination, solving distribution challenges, and encouraging public acceptance of vaccination. Addressing vaccine hesitancy will require good communication strategies on the value of being protected as an individual and the benefits for the community in reducing viral transmission.9
Published:November 04, 2020DOI
搜狗翻译:
目前,45种候选新冠肺炎疫苗正在人体内进行临床试验,其中10种疫苗处于第3阶段试验,预计一些结果可能会在2020年底前公布。如果第三阶段试验的结果令人满意,新冠肺炎疫苗的大规模部署预计要到2021年中后期才能实现。发展国内免疫规划的结构至关重要,包括确定接受疫苗接种的优先顺序、解决分配挑战以及鼓励公众接受疫苗接种。解决疫苗犹豫不决的问题需要良好的沟通策略,让人们了解作为个体受到保护的价值以及社区在减少病毒传播方面的益处。9
如上,只是原文一小部分,能在这个最world's oldest and best known的medical journalsl发表的文章的,都是经过审核的,应该不会错。就算如上文所述明年中后期才能大规模生产,最新应用的也是一线工作者和老年人,我们这种没后门的就等着吧。
Covid在美国明年前期不可能好,考虑考虑吧
The Lancet 复制的 |
|